



EXPRESS MAILING NO.: EM051490263US

PTO/SB/08A (11-07)

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/759,904
Filing Date	JANUARY 16, 2004
First Named Inventor	ERIC J. BECKMAN
Art Unit	1618
Examiner Name	JAMES WILLIAM ROGERS
Attorney Docket Number	02-012

Sheet 1 of 6

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US- 4,689,386	11-07-1985	CHAPMAN	
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			
	A12	US-			
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-			
	A17	US-			
	A18	US-			
	A19	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1					
	B2					
	B3					
	B4					
	B5					
	B6					

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/759,904
				Filing Date	JANUARY 16, 2004
				First Named Inventor	ERIC J. BECKMAN
				Art Unit	1618
				Examiner Name	JAMES WILLIAM ROGERS
Sheet	2	of	6	Attorney Docket Number	02-012

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CS1	ZHANG, J.Y. et al. A new peptide-based urethane polymer: synthesis, biodegradation, and potential to support cell growth in vitro. Biomaterials, (2000), 21, 1247-1258.	
	CS2	BECKWITH, A.C. et al.; Direct estimation of lysine in corn meals by the ninhydrin color reaction. J. Agric. Food Chem. (1975), 23, No. 2, 194-196.	
	CS3	CHRISTMORE, D., et al.; Improved recovery and stability of ethanol in automated headspace analysis. J. Forensi Sci. (1984), 29, 1038-1044	
	CS4	HELLMER, J., et al. Automatic luminometric kinetic assay of glycerol for lipolysis studies. Anal. Biochem. (1989), 177, 132-137.	
	CS5	GRUDPAN, K., et al.; Flow injection spectrophotometric or conductometric determination of ascorbic acid in a vitamin C tablet using permanganate or ammonia. Talanta, (1999), 49, 1023-1026.	
	CS6	BRUDER, S.P., et al.; Growth kinetics, self-renewal and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J.Cell Biochem. (1997), 64, 278-294.	
	CS7	ANDREONI, G., et al.; Densitometric quantification of neuronal viability by computerized image analysis. Exp. Neurol., (1997), 148, 281-287.	
	CS8	ISHAUG, S.L., et al.; Bone formation by three-dimensional stromal osteoblast culture in biodegradable polymer scaffolds. J. Biomed. Mater. Res., (1997), 36, 17-28.	
	CS9	SPAANS, C. J. et al.; A new biomedical polyurethane with a high modulus based on 1,4-butanediisocyanate and epsilon-caprolactone. Journal of Materials Science: Materials in Medicine; (1998); 9, 675-678	
	CS10	WANG, S. et al.; Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney International, (2000); 57, 1002-1014.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/759,904
				Filing Date	JANUARY 16, 2004
				First Named Inventor	ERIC J. BECKMAN
				Art Unit	1618
				Examiner Name	JAMES WILLIAM ROGERS
Sheet	3	of	6	Attorney Docket Number	02-012

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CS11	ZHENG, F. et al.; Upregulation of type I collagen by TGF-Beta in mesangial cells is blocked by PPAR gamma activation. Am. J. Physiol. Renal. Physiol.; (2002); 282, F639-F648.		
	CS12	DERYNCK, R. et al.; The murine transforming growth factor-beta precursor. J. Biol. Chem.; (1986); 261; 4377-4379.		
	CS13	LAEMMLI, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature; (1970); 227; 680-685.		
	CS14	ZHANG, J. et al.; Effect of cystathionine and cystathionine metabolites on the phosphorylation of tyrosine residues in human neutrophils. Biochem. Biophys. Res. Commun.; (1996); 224; 849-854.		
	CS15	ZHENG, W.; ZHAO, Q. Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus. Brain Res (2002); 958(2); 371-380		
	CS16	NAKAYAMA, Y. et al.; Development of high-performance stent: gelatinous photogel-coated stent that permits drug delivery and gene transfer. J Biomed Mater Res (2001); 57(4): 559-566.		
	CS17	KIM, B.S., MOONEY, D.J. Development of biocompatible synthetic extra cellular matrices for tissue engineering. Trends Biotechnol. (1998), 16, 224-230.		
	CS18	SHINOKA, T.; et al.; Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann. Thorac. Surg. (1995), 60, S513-S516.		
	CS19	FRANCESCHI, R. et al.; Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. J. Bone Miner. Res. (1994), 9, 843-854.		
	CS20	MIZUTANI, A. et al.; Expression of matrix metalloproteinases during ascorbate-induced differentiation of osteoblastic MC3T3-E1 cells. J. Bone Miner. Res. (2001), 16, 2043-2049.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/759,904
		Filing Date	JANUARY 16, 2004
		First Named Inventor	ERIC J. BECKMAN
		Art Unit	1618
		Examiner Name	JAMES WILLIAM ROGERS
Sheet 4 of 6	Attorney Docket Number	02-012	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CS21	SPAANS, C. J. et al.; High molecular weight polyurethanes and a polyurethane urea based on 1,4-butanediisocyanate. Polymer Bulletin, (1998), 41, 131-138	
	CS22	SPAANS, C. J. et al.; New biodegradable polyurethane-ureas, polyurethane and polyurethane-amide for in-vivo tissue engineering: structure-properties relationships. Polymeric Materials Science and Engineering, (2001), 85, 61-62	
	CS23	FROMSTEIN, J. D. et al.; Elastomeric biodegradable polyurethane blends for soft tissue applications. Journal of Biomaterials Science Polymer Edition, (2002) 13, 391-406 .	
	CS24	SKARJA, G. A.; WOODHOUSE, K. A.; Synthesis and characterization of degradable polyurethane elastomers containing an amino-acid based chain extender. Journal of Biomaterials Science Polymer Edition, (1998), 9, 271-295.	
	CS25	SAAD, B. et al.; Development of degradable polyesterurethanes for medical applications: In vitro and in vivo evaluations. Journal of Biomedical Materials Research, (1997), 36, 65-74	
	CS26	BORKENHAGEN, M. et al.; In vivo performance of a new biodegradable polyester urethane system used a nerve guidance channel. Biomaterials, (1998), 19, 2155-2165 .	
	CS27	KYLMA, J.; SEPPALA, J. V. Synthesis and characterization of a biodegradable thermoplastic poly(ester-urethane) elastomer. Macromolecules, (1997), 30, 2876-2882 .	
	CS28	GORNA, K. GOGOLEWSKI, S. Biodegradable polyurethanes for implants. II. In vitro degradation and calcification of materials from poly(epsilon-caprolactone)-poly(ethylene oxide) diols and various chain extenders. Journal of Biomedical Materials Research, (2002), 60, 592-606.	
	CS29	VROUWENVELDER, W. C. A. et al.; Histological and biochemical evaluation of osteoblast culture on bioactive glass, hydroxyapatite, titanium alloy, and stainless steel. J. Biomed. Mater. Res., (1993), 27, 465-475, .	
	CS30	REMES, A.; WILLIAMS, D.F. Immune response in biocompatibility, Biomaterials, (1992), 13:11, 731-743 .	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/759,904
				Filing Date	JANUARY 16, 2004
				First Named Inventor	ERIC J. BECKMAN
				Art Unit	1618
				Examiner Name	JAMES WILLIAM ROGERS
Sheet	5	of	6	Attorney Docket Number	02-012

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CS31	CHOONG, P. F. M. et al.; Effects of ascorbic acid, calcitrol, and retinoic acid on the differentiation of preosteoblasts. J. Orthop. Res., (1993), 11, 638-647, .	
	CS32	PRASHER, D. C. et al.; Primary structure of the aequorea Victoria green-fluorescent protein. Gene, (1992), 111, 229-233, .	
	CS33	HEIM, R. et al.; Wavelength mutations and posttranslational autoxidation of green fluorescent protein. Proc. Natl. Acad. Sci. USA, (1994), 91, 12501-12504.	
	CS34	CHALFIE, M. et al.; Green fluorescent protein as a marker for gene expression. Science, (1994), 263, 802-805.	
	CS35	OKABE, M. et al.; 'Green mice' as a source of ubiquitous green cells. FEBS Lett., (1997), 407, 313-319.	
	CS36	IKAWA, M. et al.; A rapid and non-invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP). FEBS Lett., (1995), 375, 125-128.	
	CS37	KIM, S. et al.; Pore structure analysis of swollen dextran-methacrylate hydrogels by SEM and mercury intrusion porosimetry. J. Biomed. Mater. Res., (2000.), 53, 258-266.	
	CS38	SHEEHAN, D.;HRAPCHAK, B. Theory and practice of histotechnology. 2nd Ed. Battelle Press, Ohio, (1980), pp 226-227.	
	CS39	REINERT, H. et al.; In situ measurement of collagen synthesis by human bone cells with a Sirius Red-based colorimetric microassay: effects of transforming growth factor BETA2 and ascorbic acid 2-phosphate. Histochem. Cell Biol., (1999), 11, 271-276, .	
	CS40	ZHANG, J. et al.; Synthesis, biodegradability, and biocompatibility of Lysine diisocyanate-glucose polymers. Tissue Engineering, (2002), 8, No. 5, 771-785 .	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/759,904		
		Filing Date	JANUARY 16, 2004		
		First Named Inventor	ERIC J. BECKMAN		
		Art Unit	1618		
		Examiner Name	JAMES WILLIAM ROGERS		
Sheet	6	of	6	Attorney Docket Number	02-012

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CS41	ZHANG, Z. et al.; Morphological, physical and chemical evaluation of the Vascugraft arterial prosthesis: comparison of a novel polyurethane device and other microporous structures. Biomaterials, (1994), 15, No. 7, 483-501.	
	CS42	ATHANASIOU, K. A. et al.; Sterilization, toxicity, biocompatibility and clinical application of polylactic acid/polyglycolic acid co-polymer. Biomaterials, (1996), 17, 93-102.	
	CS43	PENCO, M. et al.; Degradation behaviour of block copolymers containing poly(lactic-glycolic acid) and poly(ethylene glycol) segments. Biomaterials, (1996), 17, 1583-1590.	
	CS44	RAMANATHAN, R. et al.; Alcohol inhibits cell-cell adhesion mediated by human L1. J. Cell Biol., (1996), 133, 381-390, .	
	CS45	FARLEY, J. R. et al.; Direct effects of ethanol on bone resorption and formation in vitro. Arch. Biochem. Biophys., (1985), 238, 305-314.	
	CS46	BRUIN, P. et al.; Design and synthesis of biodegradable poly(ester urethane) elastomer networks composed of non toxic building blocks. Makromol. Chem., (1988), 9, 589-594.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.